ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids Geneva, Switzerland and Boston, MA – December 21, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical- stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

Holy Name Medical Center First in the Northeast to Offer Magellan(TM) Robotic System TEANECK, N.J., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Physicians at Holy Name Medical Center are the first in the Northeast to use the Magellan™ Robotic System, which enables them to perform complex,...